CLINICAL TRIALS PROFILE FOR MATULANE

All Clinical Trials for Matulane

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002944 ↗	Combination Chemotherapy in Treating Children With Progressive Brain Tumors	Completed	National Cancer Institute (NCI)	Phase 3	1997-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
NCT00002944 ↗	Combination Chemotherapy in Treating Children With Progressive Brain Tumors	Completed	Children's Oncology Group	Phase 3	1997-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
NCT00004010 ↗	Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease	Completed	National Cancer Institute (NCI)	Phase 2	1999-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving radiation therapy after chemotherapy may be an effective treatment for Hodgkin's disease. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating children who have previously untreated stage II, stage III, or stage IV Hodgkin's disease.
NCT00004010 ↗	Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease	Completed	Children's Oncology Group	Phase 2	1999-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving radiation therapy after chemotherapy may be an effective treatment for Hodgkin's disease. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating children who have previously untreated stage II, stage III, or stage IV Hodgkin's disease.
NCT00079105 ↗	A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years	Completed	Newcastle-upon-Tyne Hospitals NHS Trust	Phase 2	2004-01-01	RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating older patients with previously untreated Hodgkin's lymphoma.
NCT00335140 ↗	Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma	Terminated	National Cancer Institute (NCI)	Phase 2	2006-12-01	RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.

Clinical Trial Conditions for Matulane

Condition Name

Condition Name for Matulane
Intervention	Trials
Lymphoma	3
AIDS-related Peripheral/Systemic Lymphoma	1
AIDS-related Small Noncleaved Cell Lymphoma	1
Brain Tumors	1

Condition MeSH

Condition MeSH for Matulane
Intervention	Trials
Lymphoma	5
Hodgkin Disease	3
Precursor Cell Lymphoblastic Leukemia-Lymphoma	1
Plasmablastic Lymphoma	1

Clinical Trial Locations for Matulane

Trials by Country

Trials by Country for Matulane
Location	Trials
United States	82
Canada	11
Australia	4
United Kingdom	3
Germany	1

Trials by US State

Trials by US State for Matulane
Location	Trials
Minnesota	3
Michigan	3
Iowa	3
Wisconsin	3
Illinois	3

Clinical Trial Progress for Matulane

Clinical Trial Phase

Clinical Trial Phase for Matulane
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Matulane
Clinical Trial Phase	Trials
Completed	3
Not yet recruiting	1
Terminated	1

Clinical Trial Sponsors for Matulane

Sponsor Name

Sponsor Name for Matulane
Sponsor	Trials
National Cancer Institute (NCI)	5
Children's Oncology Group	2
Newcastle-upon-Tyne Hospitals NHS Trust	1

Sponsor Type

Sponsor Type for Matulane
Sponsor	Trials
Other	5
NIH	5
Industry	2

Matulane (Procarbazine Hydrochloride): Clinical Trials, Market Analysis, and Projections

Introduction

Matulane, also known as procarbazine hydrochloride, is a hydrazine derivative and alkylating agent used in the treatment of various types of cancer. Here, we will delve into the current clinical trials, market analysis, and future projections for this drug.

Clinical Trials Update

Ongoing and Completed Trials

Matulane is involved in several clinical trials across different cancer types:

• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma: This Phase 3 trial, initiated in 2009, is comparing the efficacy of temozolomide versus PCV chemotherapy (which includes procarbazine) in patients with anaplastic glioma or low-grade glioma. The trial is currently recruiting and is expected to complete in October 2025[1].

• Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA): This Phase 2 trial, started in 2019, is evaluating the safety and efficacy of a tailored treatment regimen that includes procarbazine in elderly patients with primary CNS lymphoma. The trial is recruiting and expected to complete by the end of 2024[1].

• Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma: This completed Phase 2 trial involved a combination chemotherapy regimen that included procarbazine. The trial was conducted by Memorial Sloan Kettering Cancer Center and completed in August 2022[1].

• Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma: Another completed Phase 2 trial, this study compared intravenous and oral chemotherapy regimens, both of which included procarbazine, in patients with HIV-associated non-Hodgkin lymphoma. The trial was completed in July 2021[1].

Mechanism of Action and Indications

Procarbazine works by inhibiting the transmethylation of methionine methyl groups to tRNA, thereby interfering with protein, RNA, and DNA synthesis. It may also directly damage DNA. It is used in the treatment of various cancers, including anaplastic glioma, CNS lymphoma, follicular lymphoma, glioblastoma, classical Hodgkin lymphoma, and mantle cell lymphoma[4].

Market Analysis

Current Market Landscape

While Matulane itself is not a new drug (it was first approved by the FDA in 1969), its continued use in combination therapies and ongoing clinical trials keep it relevant in the oncology market.

Market Trends and Drivers

The oncology market, including drugs like Matulane, is driven by several factors:

• Increasing Cancer Prevalence: The rising incidence of cancer globally increases the demand for effective cancer treatments.
• Advancements in Combination Therapies: The use of Matulane in combination with other anticancer drugs, such as in the MOPP regimen, continues to be a significant part of cancer treatment protocols[4].

Market Challenges

Despite its established use, the market for Matulane faces challenges such as:

• High Production Costs: The cost of producing and maintaining the supply of anticancer drugs can be high.
• Stringent Regulatory Requirements: Ensuring compliance with regulatory standards can be complex and costly[2].

Market Projections

Growth in Oncology Market

The overall oncology market is expected to grow significantly, driven by advancements in cancer treatments and increasing cancer prevalence. While specific projections for Matulane are not readily available, the growth in the broader oncology market is indicative of a favorable environment for established cancer treatments.

Emerging Trends

The future of cancer treatment is likely to involve more targeted and personalized therapies. However, traditional chemotherapeutic agents like Matulane will continue to play a role, especially in combination regimens.

Antibody Drug Conjugates and Future Innovations

The market for antibody drug conjugates (ADCs), which are more targeted and potentially less toxic than traditional chemotherapies, is growing rapidly. However, traditional alkylating agents like Matulane will remain relevant due to their established efficacy and role in combination therapies. The ADC market is expected to grow at a CAGR of 11.8% from 2024 to 2030, reaching $25.99 billion by 2030, but this does not necessarily replace the need for drugs like Matulane[2].

Key Takeaways

• Clinical Trials: Matulane is involved in several ongoing and completed clinical trials, highlighting its continued relevance in cancer treatment.
• Mechanism and Indications: It works by interfering with DNA, RNA, and protein synthesis and is used in treating various types of cancer.
• Market Analysis: The oncology market is driven by increasing cancer prevalence and advancements in combination therapies, but faces challenges like high production costs and regulatory requirements.
• Market Projections: The overall oncology market is expected to grow, with traditional chemotherapies like Matulane continuing to play a significant role.

FAQs

What is Matulane used for?

Matulane (procarbazine hydrochloride) is used in the treatment of various cancers, including anaplastic glioma, CNS lymphoma, follicular lymphoma, glioblastoma, classical Hodgkin lymphoma, and mantle cell lymphoma[4].

How does Matulane work?

Matulane works by inhibiting the transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis, and may also directly damage DNA[4].

What are the current clinical trials involving Matulane?

Matulane is involved in several clinical trials, including studies on anaplastic glioma, CNS lymphoma, and HIV-associated non-Hodgkin lymphoma[1].

What are the market drivers for Matulane?

The market for Matulane is driven by increasing cancer prevalence and advancements in combination therapies[4].

What challenges does the market for Matulane face?

The market faces challenges such as high production costs and stringent regulatory requirements[2].

How is the oncology market expected to grow?

The overall oncology market is expected to grow significantly, driven by increasing cancer prevalence and advancements in cancer treatments. The ADC market, in particular, is expected to grow at a CAGR of 11.8% from 2024 to 2030[2].

References

1. LARVOL VERI, Trials - Matulane (procarbazine hydrochloride), LARVOL VERI.
2. GlobeNewswire, Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030), GlobeNewswire.
3. Prime Therapeutics, Quarterly Drug Pipeline: October 2024, Prime Therapeutics.
4. HemOnc.org, Procarbazine (Matulane), HemOnc.org.